全文获取类型
收费全文 | 205篇 |
免费 | 4篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 9篇 |
妇产科学 | 5篇 |
基础医学 | 8篇 |
临床医学 | 29篇 |
内科学 | 56篇 |
皮肤病学 | 1篇 |
神经病学 | 26篇 |
特种医学 | 3篇 |
外科学 | 4篇 |
综合类 | 26篇 |
预防医学 | 20篇 |
眼科学 | 2篇 |
药学 | 15篇 |
中国医学 | 4篇 |
出版年
2023年 | 1篇 |
2021年 | 4篇 |
2020年 | 4篇 |
2019年 | 13篇 |
2018年 | 10篇 |
2017年 | 7篇 |
2016年 | 10篇 |
2015年 | 6篇 |
2014年 | 34篇 |
2013年 | 21篇 |
2012年 | 10篇 |
2011年 | 19篇 |
2010年 | 19篇 |
2009年 | 11篇 |
2008年 | 9篇 |
2007年 | 16篇 |
2006年 | 8篇 |
2005年 | 5篇 |
2004年 | 2篇 |
排序方式: 共有209条查询结果,搜索用时 281 毫秒
1.
男性青少年性腺功能减退症患者短期雄激素替代治疗对血脂和hsCRP水平的影响 总被引:1,自引:0,他引:1
目的 探讨性腺功能低减的青少年男性,短期雄激素替代治疗对血脂和超敏C反应蛋白(hsCRP)的影响。方法 本研究为前瞻性自身对照研究,共纳入33例性腺功能减退青少年男性。行短期(9个月)雄激素替代治疗,比较治疗前后血睾酮水平、第二性征发育程度、身高、握力、血红蛋白、血脂和hsCRP的差异。结果 (1)替代治疗后,睾酮水平明显升高,第二性征明显发育,身高、握力、血红蛋白显著增加(P值均〈0.05);(2)短期雄激素替代治疗后,总胆固醇(TC),低密度脂蛋白(LDL-c),高密度脂蛋白(HDL-c)和甘油三酯(TG)部有所下降,但无统计学差异(P〉0.5)。超敏CRP显著下降(P=0.025)。结论 (1)性腺功能低减的青少年男性,短期雄激素替代治疗,可以促进第二性征发育,增加身高、握力和血红蛋白;(2)短期雄激素替代治疗,对血脂无显著性影响。但是,可以使hsCRP明显下降。 相似文献
2.
《Indian heart journal》2018,70(3):346-349
BackgroundCurrently, it is not clear whether recurrent traumatic events lead to progression of rheumatic heart disease (RHD) after the incident of acute rheumatic fever or a persistent inflammatory state at the site of the valves. The aim of this study was to assess the possible association between plasma high sensitive C Reactive Protein (hs-CRP) level as an indicator of inflammation and RHD.Materials & methodsNinety patients with RHD and 90 healthy controls who had undergone complete echocardiographic examination were enrolled in this cross-sectional study. A score was given to each patient according to the severity of valvular involvement. Plasma hs-CRP level was checked for each patient by ELISA method twice with two-week interval, and the mean hs-CRP was calculated.ResultsThe mean plasma hs-CRP level in the case group was significantly higher compared to its level in the control group (2.59 ± 4.82 and 0.55 ± 0.43 in the case and control groups respectively, p < 0.001). There was also a strong association between the level of plasma hs-CRP and the severity of rheumatic valvular involvement (p < 0.001).ConclusionThe mean plasma hs-CRP level seems to have a significant association with RHD and its severity. Further studies are needed to determine the cause and effect relationship. 相似文献
3.
Mufide Oncel Seval Akbulut Turkan Toka Ozer Aysel Kiyici Mustafa Keles Beyhan Baltaci 《Renal failure》2016,38(7):1071-1075
Background: Cytokines are essential mediators of immune response. Chronic renal failure patients suffer from chronic inflammation that results from factors such as impaired renal function, accumulation of uremic toxins and bio incompatibility of dialyzer membranes. These patients are also at increased risk of cardiovascular diseases. We have evaluated cytokines, adipocytokines and inflammatory markers in patients with chronic renal failure undergoing hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD).Material and methods: We have determined serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), leptin and ghrelin levels of chronic renal failure patients treated with either HD (n?=?20) or CAPD (n?=?20). TNF-α, IL-6, ghrelin and leptin measurements were performed by commercially available kits based on enzyme-linked immunosorbent assay (ELISA) method. hsCRP levels were determined by turbidimetric methods.Results: Serum TNF-α and IL-6 levels of patients on HD were significantly higher than those of the ones on CAPD (p?<?0.05). Ghrelin, leptin and hsCRP concentrations were similar in both groups.Conclusions: We can conclude that cytokine production is more obvious in HD process. 相似文献
4.
T. Sathyapalan M. Aye A.S. Rigby N.J. Thatcher S.R. Dargham E.S. Kilpatrick S.L. Atkin 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2018,28(7):691-697
Background
Hormone replacement therapy may be beneficial for cardiovascular disease risk (CVR) in post-menopausal women. Soy isoflavones may act as selective estrogen receptor modulators. The aim of this study was to evaluate whether soy isoflavones had an effect on CVR markers.Methods
The expected 10-year risk of cardiovascular disease and mortality were calculated as a secondary endpoint from a double blind randomised parallel study involving 200 women (mean age 55 years, Caucasian, Hull, UK, 2012) in the early menopause who were randomised to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (depleted of all isoflavones; SP) given as a snack bar between meals daily for 6 months. Age, diabetes, smoking, blood pressure and lipid profiles were used to calculate CVR using the Framingham CVR engine.Results
SPI treatment resulted in a significant reduction in the metabolic parameters and systolic blood pressure compared to SP (p < 0.01). There were no changes in fasting lipid profile and diastolic blood pressure with either treatment. At 6 months, changes in these parameters with SPI treatment were reflected in a calculated 27% (p < 0.01) reduction in 10 year coronary heart disease risk, a 37% (p < 0.01) reduction in myocardial infarction risk, a 24% (p < 0.04) reduction in cardiovascular disease and 42% (p < 0.02) reduction in cardiovascular disease death risk.Conclusions
Supplementation with soy protein with isoflavones for 6 months significantly improved CVR markers and calculated CVR at 6 months during early menopause compared to soy protein without isoflavones.ISRCTN registry
ISRCTN34051237. 相似文献5.
Brendan M. Everett Marc Y. Donath Aruna D. Pradhan Tom Thuren Prem Pais Jose C. Nicolau Robert J. Glynn Peter Libby Paul M Ridker 《Journal of the American College of Cardiology》2018,71(21):2392-2401
Background
Subclinical inflammation mediated in part by interleukin (IL)-1β participates in peripheral insulin resistance and impaired pancreatic insulin secretion.Objectives
The authors tested the hypothesis that the IL-1β inhibitor canakinumab reduces incident diabetes.Methods
The authors randomized 10,061 patients with prior myocardial infarction and high-sensitivity C-reactive protein (hsCRP) ≥2 mg/l to placebo or canakinumab at doses of 50 mg, 150 mg, or 300 mg subcutaneously once every 3 months. The authors tested the effects of canakinumab on major cardiovascular events in patients with and without diabetes at baseline, and evaluated as a pre-specified analysis whether canakinumab would reduce the risk of adjudicated cases of new-onset type 2 diabetes among those with protocol-defined pre-diabetes at trial entry. The authors also evaluated the effect of canakinumab on fasting plasma glucose and glycosylated hemoglobin (HbA1c) in patients with and without established diabetes.Results
Of the participants, 4,057 (40.3%) had baseline diabetes, 4,960 (49.3%) had pre-diabetes, and 1,044 (10.4%) had normal glucose levels. Among those without diabetes, increasing tertiles of hsCRP at baseline associated with an increased risk of developing diabetes during the median follow-up period of 3.7 years (incidence rates 3.2, 4.1, and 4.4 per 100 person-years; p = 0.003). Canakinumab 150 mg as compared with placebo had similar magnitude effects on major cardiovascular event rates among those with diabetes (hazard ratio [HR]: 0.85; 95% confidence interval [CI]: 0.70 to 1.03), pre-diabetes (HR: 0.86; 95% CI: 0.70 to 1.06), and normoglycemia (HR: 0.81; 95% CI: 0.49 to 1.35). Despite large reductions in hsCRP and IL-6, canakinumab did not reduce the incidence of new-onset diabetes, with rates per 100 person-years in the placebo, 50 mg, 150 mg, and 300 mg canakinumab groups of 4.2, 4.2, 4.4, and 4.1, respectively (log-rank p = 0.84). The HR comparing all canakinumab doses to placebo was 1.02 (95% CI: 0.87 to 1.19; p = 0.82). Canakinumab reduced HbA1c during the first 6 to 9 months of treatment, but no consistent long-term benefits on HbA1c or fasting plasma glucose were observed.Conclusions
Although IL-1β inhibition with canakinumab had similar effects on major cardiovascular events among those with and without diabetes, treatment over a median period of 3.7 years did not reduce incident diabetes. (Canakinumab Anti-inflammatory Thrombosis Outcomes Study [CANTOS]; NCT01327846) 相似文献6.
Serum hsCRP and procalcitonin levels in dyspeptic patients infected with CagA‐positive Helicobacter pylori 下载免费PDF全文
7.
8.
Roza Chaireti Rupesh Rajani Annika Bergquist Tor Melin Inga-Lill Friis-Liby Marjo Kapraali Stergios Kechagias Tomas L. Lindahl Sven Almer 《Thrombosis research》2014
Introduction
In recent years there have been increasing evidence associating liver disease with hypercoagulability, rather than bleeding. The aim of the study was to evaluate the haemostatic potential in patients with liver disease.Patients and methods
We measured thrombin generation in the presence and absence of thrombomodulin in patients with portal vein thrombosis (PVT, n = 47), Budd-Chiari syndrome (BCS, n = 15) and cirrhosis (n = 24) and compared the results to those obtained from healthy controls (n = 21). Fifteen patients with PVT and 10 patients with BCS were treated with warfarin and were compared to an equal number of patients with atrial fibrillation matched for prothrombin time-international normalized ratio. We assessed resistance to thrombomodulin by using ratios [marker measured in the presence/absence of thrombomodulin].Results
There were no differences in thrombin generation between patients on warfarin treatment and their controls. Cirrhotic patients generated more thrombin in the presence of thrombomodulin and exhibited thrombomodulin resistance compared to controls [p = 0.006 for endogenous thrombin potential (ETP) and p < 0.001 for peak thrombin and both ratios ETP and peak] and patients with non-cirrhotic PVT (p = 0.001, p = 0.006, p < 0.001, p < 0.001 for ETP, peak, ratio ETP, ratio peak, respectively). The patients with cirrhotic PVT exhibited higher ETP (p = 0.044) and peak (p = 0.02) in the presence of thrombomodulin than controls, as well as thrombomodulin resistance (ETP and peak ratios: p = 0.001).Conclusions
Hypercoagulability and thrombomodulin resistance in patients with cirrhosis were independent of the presence of splanchnic vein thrombosis. The hypercoagulability in patients with cirrhotic PVT could have implications for considering longer or more intensive treatment with anticoagulants in this group. 相似文献9.
《吉林医学》2016,(11)
目的:研究高血压患者血清同型半胱氨酸(HCY)、尿酸(UA)、超敏C-反应蛋白(hs-CRP)及脂蛋白a(LPa)含量的变化。方法:选择高血压患者110例作为观察组,另选择同期进行体检的健康者110例作为对照组。检测两组受检者血清同型半胱氨酸、尿酸、超敏C-反应蛋白及脂蛋白a水平,并进行统计学分析。结果:观察组中的HCY、UA、hs-CRP及LPa血清水平显著高于对照组,差异有统计学意义(P<0.05)。在观察组中,HCY、UA、hs-CRP及LPa单一检测及4项联检的阳性率显著高于对照组,差异有统计学意义(P<0.05)。结论:高血压患者同型半胱氨酸、尿酸、超敏C-反应蛋白及脂蛋白a水平显著高于正常人,检测HCY、UA、hs-CRP及LPa可给临床治疗提供参考,值得临床推广应用。 相似文献
10.
Matthew J. Gurka Christa L. Lilly M. Norman Oliver Mark D. DeBoer 《Metabolism: clinical and experimental》2014